GREENWICH LIFESCIENCES INC

GLSINASDAQ

🏆 #3489 by market capEarnings Nov 12US Equity

$1,021.64▲ $63.24 (+6.19%)

Simulated price

🔔

Track GLSI

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 6.2%

7d▲ 5125.8%

14d▲ 6275.3%

30d▲ 6419.7%

ytd▲ 4710.0%

1y▲ 9955.5%

🏦Market Cap

$267M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Good

Trading Snapshot

Day Range: $1,013.86 – $1,038.50
52-Week Range: $7.78 – $34.10
Volume: $3.54B
Avg Volume: $4.27B
Shares Outstanding: 14.7M
Next Earnings: Nov 18, 2026

Fundamentals Snapshot

Annual Revenue: $21M
Last Q Revenue: $6M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-1.53
Dividend Yield: —
Dilution (1yr): +3.7%

Why Investors Own GLSI

✓High-growth profile — revenue up +44.1% YoY with expanding US Equity exposure.
✓Healthy economics — 69% gross margin and 7% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

GREENWICH LIFESCIENCES INC

GLSI

Financial Trends

Revenue

$0▲ +0.0% YoY

Operating Income

−$19M▲ +10.3% YoY

Free Cash Flow

−$10M▲ +36.4% YoY

Shares Outstanding

13.6M▲ +3.7% YoY

Net Cash

$6M▲ +$2M YoY

StockOtter · stockotter.space

About GREENWICH LIFESCIENCES INC

Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.

🦦